Site Search

Search
Showing 1 - 10 of 41 results
About the CF Foundation | CFTR Modulators | Our Research Approach
New Cystic Fibrosis Drug Brings Gift of a Future, NPR Reports Online
News |
| 1 min read
About the CF Foundation | CFTR Modulators
New Hope of Kalydeco (VX-770) Makes Headlines and Newscasts Around the Nation
News |
| 2 min read
CFTR Modulators
New England Journal of Medicine Publishes Study about VX-770 — A Promising Drug That Targets Underlying Defect in CF

The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.

News |
| 3 min read
About the CF Foundation | CFTR Modulators | Our Research Approach
Foundation Makes Milestone Payment to Collaborator for Potential Dual-Acting Compound
News |
| 1 min read
About the CF Foundation | CFTR Modulators
Foundation Showcased in BusinessWeek
News |
| 1 min read
About the CF Foundation | CFTR Modulators
Promising Data For CF Drug Published in The Lancet
News |
| 1 min read
About the CF Foundation | Cystic Fibrosis Foundation Therapeutics (CFFT) | CFTR Modulators
CF Foundation-Funded Technology Licensed by Calif. Biopharmaceutical Co.
News |
| 2 min read
Research | CFTR Modulators | Drug Pipeline
FDA Expands Use of Orkambi® to Children With CF Ages 2 to 5

The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.

News |
| 3 min read
About the CF Foundation | CFTR Modulators
The New York Times and Other Major Media Outlets Feature Results of VX-770 Trial
News |
| 2 min read
About the CF Foundation | CFTR Modulators
Wall Street Journal Health Blog: CF Foundation Not Just a Cheerleader
News |
| 2 min read